Cidara Therapeutics Inc. (CDTX) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Cidara Therapeutics Inc. faces a significant risk due to its delayed filing of the Annual Report on Form 10-K for the year ended December 31, 2023, which renders them ineligible to use Form S-3 for registering securities. This situation could hinder their ability to raise capital efficiently until at least May 1, 2025, as they must first ensure timely filing of all periodic reports under the Exchange Act. The increased transaction costs and time required to register additional securities may impede their strategic plans and financial stability. The uncertainty surrounding their ability to meet future filing deadlines further exacerbates the potential adverse effects on their business operations.
The average CDTX stock price target is $34.50, implying 45.82% upside potential.
To learn more about Cidara Therapeutics Inc.’s risk factors, click here.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com